|
1
|
Santana SS, Gennari-Cardoso ML, Carvalho
FC, Roque-Barreira MC, Santiago AS, Alvim FC and Pirovani CP:
Eutirucallin, a RIP-2 type lectin from the latex of Euphorbia
tirucalli L. presents proinflammatory properties. PLoS One.
9:e884222014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Girbes T, Ferreras JM, Arias FJ, Muñoz R,
Iglesias R, Jimenez P, Rojo MA, Arias Y, Perez Y, Benitez J, et al:
Non-toxic type 2 ribosome-inactivating proteins (RIPs) from
Sambucus: Occurrence, cellular and molecular activities and
potential uses. Cell Mol Biol (Noisy-le-grand). 49:537–545.
2003.
|
|
3
|
He WJ and Liu WY: Cinnamomin: A
multifunctional type II ribosome-inactivating protein. Int J
Biochem Cell Biol. 35:1021–1027. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stirpe F: Ribosome-inactivating proteins.
Toxicon. 44:371–383. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Walsh MJ, Dodd JE and Hautbergue GM:
Ribosome-inactivating proteins: Potent poisons and molecular tools.
Virulence. 4:774–784. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hartley MR and Lord JM: Cytotoxic
ribosome-inactivating lectins from plants. Biochim Biophys Acta.
1701:1–14. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stirpe F and Battelli MG:
Ribosome-inactivating proteins: Progress and problems. Cell Mol
Life Sci. 63:1850–1866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peumans WJ, Hao Q and Van Damme EJ:
Ribosome-inactivating proteins from plants: more than RNA
N-glycosidases? FASEB J. 15:1493–1506. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fong WP, Mock WY and Ng TB: Intrinsic
ribonuclease activities in ribonuclease and ribosome-inactivating
proteins from the seeds of bitter gourd. Int J Biochem Cell Biol.
32:571–577. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horrix C, Raviv Z, Flescher E, Voss C and
Berger MR: Plant ribosome-inactivating proteins type II induce the
unfolded protein response in human cancer cells. Cell Mol Life Sci.
68:1269–1281. 2011. View Article : Google Scholar
|
|
11
|
de Virgilio M, Lombardi A, Caliandro R and
Fabbrini MS: Ribosome-inactivating proteins: From plant defense to
tumor attack. Toxins (Basel). 2:2699–2737. 2010. View Article : Google Scholar
|
|
12
|
Nielsen K and Boston RS:
Ribosome-inactivating proteins: A plant perspective. Annu Rev Plant
Physiol Plant Mol Biol. 52:785–816. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Massa S, Paolini F, Spanò L, Franconi R
and Venuti A: Mutants of plant genes for developing cancer
vaccines. Hum Vaccin. 7(Suppl): 147–155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zarovni N, Vago R and Fabbrini MS: Saporin
suicide gene therapy. Methods Mol Biol. 542:261–283. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Preijers FW: Rationale for the clinical
use of immunotoxins: Monoclonal antibodies conjugated to
ribosome-inactivating proteins. Leuk Lymphoma. 9:293–304. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Voss C, Eyol E and Berger MR:
Identification of potent anti-cancer activity in Ximenia americana
aqueous extracts used by African traditional medicine. Toxicol Appl
Pharmacol. 211:177–187. 2006. View Article : Google Scholar
|
|
17
|
Voss C, Eyol E, Frank M, von der Lieth CW
and Berger MR: Identification and characterization of riproximin, a
new type II ribosome-inactivating protein with antineoplastic
activity from Ximenia americana. FASEB J. 20:1194–1196. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bayer H, Ey N, Wattenberg A, Voss C and
Berger MR: Purification and characterization of riproximin from
Ximenia americana fruit kernels. Protein Expr Purif. 82:97–105.
2012. View Article : Google Scholar
|
|
19
|
Bayer H, Essig K, Stanzel S, Frank M,
Gildersleeve JC, Berger MR and Voss C: Evaluation of riproximin
binding properties reveals a novel mechanism for cellular
targeting. J Biol Chem. 287:35873–35886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adwan H, Bayer H, Pervaiz A, Sagini M and
Berger MR: Riproximin is a recently discovered type II ribosome
inactivating protein with potential for treating cancer. Biotechnol
Adv. 32:1077–1090. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Adwan H, Murtaja A, Kadhim Al-Taee K,
Pervaiz A, Hielscher T and Berger MR: Riproximin's activity depends
on gene expression and sensitizes PDAC cells to TRAIL. Cancer Biol
Ther. 15:1185–1197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Kodama T, Doukas AG and Hamblin MR:
Delivery of ribosome-inactivating protein toxin into cancer cells
with shock waves. Cancer Lett. 189:69–75. 2003. View Article : Google Scholar
|
|
24
|
Gasperi-Campani A, Musa AR and Roncuzzi L:
Diverse activity of sc-RIP saporin 6 on primary and metastatic
melanoma cells in vitro. Melanoma Res. 3:363–367. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang C, Yang A, Zhang B, Yin Q, Huang H,
Chen M and Xie J: PANC-1 pancreatic cancer cell growth inhibited by
cucurmosin alone and in combination with an epidermal growth factor
receptor-targeted drug. Pancreas. 43:291–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Podlech O, Harter PN, Mittelbronn M,
Poschel S and Naumann U: Fermented mistletoe extract as a
multimodal antitumoral agent in gliomas. eCAM.
2012:5017962012.PubMed/NCBI
|
|
27
|
Mohamed MS, Veeranarayanan S, Poulose AC,
Nagaoka Y, Minegishi H, Yoshida Y, Maekawa T and Kumar DS: Type 1
ribotoxin-curcin conjugated biogenic gold nanoparticles for a
multimodal therapeutic approach towards brain cancer. Biochim
Biophys Acta. 1840:1657–1669. 2014. View Article : Google Scholar
|
|
28
|
Wei F, Cao S, Ren X, Liu H, Yu J, Li H and
Hao X: Efficient antiproliferative and antiangiogenic effects on
human ovarian cancer growth by gene transfer of attenuated mutants
of Shiga-like toxin I. Int J Gynecol Cancer. 18:677–691. 2008.
View Article : Google Scholar
|
|
29
|
Fan X, He L and Meng Y, Li G, Li L and
Meng Y: A-MMC and MAP30, two ribosome-inactivating proteins
extracted from Momordica charantia, induce cell cycle arrest and
apoptosis in A549 human lung carcinoma cells. Mol Med Rep.
11:3553–3558. 2015.PubMed/NCBI
|
|
30
|
Fang EF, Zhang CZ, Ng TB, Wong JH, Pan WL,
Ye XJ, Chan YS and Fong WP: Momordica charantia lectin, a type II
ribosome inactivating protein, exhibits antitumor activity toward
human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer
Prev Res (Phila). 5:109–121. 2012. View Article : Google Scholar
|
|
31
|
Narayanan S, Surendranath K, Bora N,
Surolia A and Karande AA: Ribosome inactivating proteins and
apoptosis. FEBS Lett. 579:1324–1331. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gan YH, Peng SQ and Liu HY: Molecular
mechanism of apoptosis induced by ricin in HeLa cells. Acta
Pharmacol Sin. 21:243–248. 2000.
|
|
33
|
Garrosa M, Jiménez P, Tejero J, Cabrero P,
Cordoba-Diaz D, Quinto EJ, Gayoso MJ and Girbés T: Toxicity of the
anti-ribosomal Lectin Ebulin f in lungs and intestines in elderly
mice. Toxins (Basel). 7:367–379. 2015. View Article : Google Scholar
|
|
34
|
Zhang D, Chen B, Zhou J, Zhou L, Li Q, Liu
F, Chou KY, Tao L and Lu LM: Low concentrations of trichosanthin
induce apoptosis and cell cycle arrest via c-Jun N-terminal protein
kinase/mitogen-activated protein kinase activation. Mol Med Rep.
11:349–356. 2015.
|
|
35
|
Grimm S and Noteborn M: Anticancer genes:
Inducers of tumour-specific cell death signalling. Trends Mol Med.
16:88–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tian H, Wang J, Zhang B, Di J, Chen F, Li
H, Li L, Pei D and Zheng J: MDA-7/IL-24 induces Bcl-2
denitrosylation and ubiq-uitin-degradation involved in cancer cell
apoptosis. PLoS One. 7:e372002012. View Article : Google Scholar
|
|
37
|
Dalloul A and Sainz-Perez A:
Interleukin-24: A molecule with potential anti-cancer activity and
a cytokine in search of a function. Endocr Metab Immune Disord Drug
Targets. 9:353–360. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Emdad L, Lebedeva IV, Su ZZ, Gupta P,
Sauane M, Dash R, Grant S, Dent P, Curiel DT, Sarkar D, et al:
Historical perspective and recent insights into our understanding
of the molecular and biochemical basis of the antitumor properties
of mda-7/IL-24. Cancer Biol Ther. 8:391–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gupta P, Su ZZ, Lebedeva IV, Sarkar D,
Sauane M, Emdad L, Bachelor MA, Grant S, Curiel DT and Dent P:
mda-7/IL-24: Multifunctional cancer-specific apoptosis-inducing
cytokine. Pharmacol Ther. 111:596–628. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Choi Y, Roh MS, Hong YS, Lee HS and Hur
WJ: Interleukin-24 is correlated with differentiation and lymph
node numbers in rectal cancer. World J Gastroenterol. 17:1167–1173.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ellerhorst JA, Prieto VG, Ekmekcioglu S,
Broemeling L, Yekell S, Chada S and Grimm EA: Loss of MDA-7
expression with progression of melanoma. J Clin Oncol.
20:1069–1074. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Patani N, Douglas-Jones A, Mansel R, Jiang
W and Mokbel K: Tumour suppressor function of MDA-7/IL-24 in human
breast cancer. Cancer Cell Int. 10:292010.PubMed/NCBI
|
|
43
|
Xu S, Oshima T, Imada T, Masuda M, Debnath
B, Grande F, Garofalo A and Neamati N: Stabilization of MDA-7/IL-24
for colon cancer therapy. Cancer Lett. 335:421–430. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Whitaker EL, Filippov VA and
Duerksen-Hughes PJ: Interleukin 24: Mechanisms and therapeutic
potential of an anti-cancer gene. Cytokine Growth Factor Rev.
23:323–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sarkar D, Su ZZ, Lebedeva IV, Sauane M,
Gopalkrishnan RV, Valerie K, Dent P and Fisher PB: mda-7 (IL-24)
mediates selective apoptosis in human melanoma cells by inducing
the coordinated overexpression of the GADD family of genes by means
of p38 MAPK. Proc Natl Acad Sci USA. 99:10054–10059. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cretu A, Sha X, Tront J, Hoffman B and
Liebermann DA: Stress sensor Gadd45 genes as therapeutic targets in
cancer. Cancer Ther. 7A:268–276. 2009.
|
|
47
|
McCullough KD, Martindale JL, Klotz LO, Aw
TY and Holbrook NJ: Gadd153 sensitizes cells to endoplasmic
reticulum stress by down-regulating Bcl2 and perturbing the
cellular redox state. Mol Cell Biol. 21:1249–1259. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hollander MC, Sheikh MS, Yu K, Zhan Q,
Iglesias M, Woodworth C and Fornace AJ Jr: Activation of Gadd34 by
diverse apoptotic signals and suppression of its growth inhibitory
effects by apoptotic inhibitors. Int J Cancer. 96:22–31. 2001.
View Article : Google Scholar : PubMed/NCBI
|
